| Size | Price | Stock | Qty |
|---|---|---|---|
| 5mg |
|
||
| 10mg |
|
||
| 25mg |
|
||
| 50mg |
|
||
| Other Sizes |
| Targets |
ML-095 targets placental alkaline phosphatase (PLAP), an enzyme that catalyzes the hydrolysis of phosphate groups from many types of molecules. It is a selective inhibitor with an IC₅₀ of 3.7 μM and shows high selectivity against TNAP and IAP (IC₅₀ > 100 μM).
|
|---|---|
| ln Vitro |
In vitro, ML-095 is a biochemical inhibitor of PLAP with an IC₅₀ of 3.7 μM. It demonstrates high selectivity against the related alkaline phosphatases TNAP and IAP (IC₅₀ > 100 μM). The compound is useful for elucidating the key biological functions and natural substrates of human PLAP.
|
| ln Vivo |
In vivo data for ML-095 are limited in the available literature. As a PLAP inhibitor, it may have potential for research in placental function and alkaline phosphatase-related pathways. Further in vivo studies are needed to evaluate its therapeutic potential.
|
| Enzyme Assay |
ML-095's PLAP inhibition activity can be characterized using biochemical assays with purified PLAP enzyme. The compound inhibits PLAP with an IC₅₀ of 3.7 μM. Selectivity against TNAP and IAP can be assessed (IC₅₀ > 100 μM).
|
| Cell Assay |
In vitro cell experiments with ML-095 involve treating cells expressing PLAP with the compound and measuring alkaline phosphatase activity. The compound's effects on PLAP function and its selectivity can be assessed.
|
| Animal Protocol |
In vivo animal studies with ML-095 have not been extensively reported in the available literature. The compound is primarily used for in vitro research. Further studies are needed to evaluate its in vivo efficacy and safety.
|
| ADME/Pharmacokinetics |
Pharmacokinetic data for ML-095 are not available in the searched literature. As a small molecule with a molecular weight of 282.72, the compound may have reasonable bioavailability. The compound is soluble in DMSO at 10 mg/mL.
|
| Toxicity/Toxicokinetics |
ML-095 is considered safe for research use at typical concentrations. As a research compound, it is intended for laboratory use only and not for human consumption. The compound should be handled under standard laboratory safety practices.
|
| Additional Infomation |
ML-095 is a biochemical inhibitor of PLAP with an IC₅₀ of 3.7 μM. It demonstrates high selectivity against TNAP and IAP (IC₅₀ > 100 μM). It has a molecular formula of C₁₃H₁₅ClN₂O₃ and a molecular weight of 282.72.
|
| Molecular Formula |
C13H15CLN2O3
|
|---|---|
| Molecular Weight |
282.722802400589
|
| Exact Mass |
282.077
|
| Elemental Analysis |
C, 55.23; H, 5.35; Cl, 12.54; N, 9.91; O, 16.98
|
| CAS # |
1135318-57-8
|
| Related CAS # |
1135318-57-8 (HCl);
|
| PubChem CID |
25067483
|
| Appearance |
Solid powder
|
| Hydrogen Bond Donor Count |
3
|
| Hydrogen Bond Acceptor Count |
4
|
| Rotatable Bond Count |
4
|
| Heavy Atom Count |
19
|
| Complexity |
298
|
| Defined Atom Stereocenter Count |
0
|
| SMILES |
C(N1C=CN=C1CC)C(C1C=CC(O)=C(O)C=1)=O.Cl
|
| Synonyms |
ML095 HCl; ML-095; ML 095; CID-25067483 hydrochloride; CID25067483; CID 25067483; MLS-0315848 hydrochloride; MLS 0315848; MLS0315848;
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month Note: Please store this product in a sealed and protected environment (e.g. under nitrogen), avoid exposure to moisture and light. |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
DMSO : ~125 mg/mL (~442.13 mM)
|
|---|---|
| Solubility (In Vivo) |
Solubility in Formulation 1: ≥ 2.08 mg/mL (7.36 mM) (saturation unknown) in 10% DMSO + 40% PEG300 + 5% Tween80 + 45% Saline (add these co-solvents sequentially from left to right, and one by one), clear solution.
For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 20.8 mg/mL clear DMSO stock solution to 400 μL PEG300 and mix evenly; then add 50 μL Tween-80 to the above solution and mix evenly; then add 450 μL normal saline to adjust the volume to 1 mL. Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH₂ O to obtain a clear solution. Solubility in Formulation 2: ≥ 2.08 mg/mL (7.36 mM) (saturation unknown) in 10% DMSO + 90% Corn Oil (add these co-solvents sequentially from left to right, and one by one), clear solution. For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 20.8 mg/mL clear DMSO stock solution to 900 μL of corn oil and mix evenly. (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 3.5371 mL | 17.6853 mL | 35.3707 mL | |
| 5 mM | 0.7074 mL | 3.5371 mL | 7.0741 mL | |
| 10 mM | 0.3537 mL | 1.7685 mL | 3.5371 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
